What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Cancer Immunotherapy Trials 2026: CAR-T, Checkpoint Inhibitors & mRNA Vaccines

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Immunotherapy has transformed cancer treatment over the past decade, and 2026 marks a turning point with personalized mRNA cancer vaccines entering late-stage trials, CAR-T cell therapy expanding beyond blood cancers, and next-generation checkpoint inhibitors showing activity in previously untreatable tumors. This guide explains each approach and how cancer patients can access these trials.

Checkpoint Inhibitors: The Foundation of Cancer Immunotherapy

Checkpoint inhibitors block proteins that cancer cells use to hide from the immune system. The most studied targets are PD-1/PD-L1 (pembrolizumab, nivolumab, atezolizumab) and CTLA-4 (ipilimumab). These drugs have produced durable responses — sometimes complete remissions lasting years — in melanoma, lung cancer, bladder cancer, and many other tumor types.

In 2026, trials are focused on combination approaches: combining two checkpoint inhibitors, or pairing a checkpoint inhibitor with targeted therapy, chemotherapy, or radiation. LAG-3 inhibitors (relatlimab, combined with nivolumab as Opdualag) represent the newest approved target, and TIGIT, TIM-3, and VISTA inhibitors are in late-phase trials.

CAR-T Cell Therapy: Engineering Your Own Immune Cells

CAR-T (chimeric antigen receptor T-cell) therapy involves removing a patient's T-cells, genetically engineering them to recognize a specific cancer target, expanding them in a laboratory, and infusing them back. Currently approved CAR-T therapies target B-cell cancers (leukemia, lymphoma, multiple myeloma).

The major breakthrough area in 2026 is solid tumor CAR-T. The IMA203 trial targeting PRAME showed significant responses in melanoma patients who had failed multiple prior lines of therapy. Similar approaches are being tested for lung cancer, ovarian cancer, and sarcoma. Challenges include T-cell exhaustion, the immunosuppressive tumor microenvironment, and cytokine release syndrome management.

Off-the-shelf (allogeneic) CAR-T uses donor T-cells rather than the patient's own cells, making treatment available immediately rather than after a 3–4 week manufacturing process. Multiple Phase 1/2 trials are testing allogeneic CAR-T products for various hematologic malignancies.

Personalized mRNA Cancer Vaccines

Following the success of mRNA COVID-19 vaccines, Moderna and Merck are developing individualized neoantigen vaccines — mRNA sequences encoding mutations unique to each patient's tumor. The mRNA-4157/V940 program (combined with pembrolizumab) showed a 44% reduction in recurrence or death compared to pembrolizumab alone in resected high-risk melanoma in a Phase 2b trial. Phase 3 trials are now enrolling.

BioNTech's autogene cevumeran (combined with atezolizumab and chemotherapy) showed promising results in pancreatic cancer — historically one of the least immunotherapy-responsive tumor types — with some patients showing durable T-cell responses. These results are generating significant interest and follow-on trials.

Who Can Participate in Immunotherapy Trials?

Eligibility for cancer immunotherapy trials depends heavily on:

Tumor type and stage: Most trials specify exact cancer type, histology, and stage (e.g., "Stage III/IV non-small cell lung cancer")
Biomarker status: PD-L1 expression, MSI/MMR status, tumor mutational burden (TMB), and specific gene mutations are commonly required
Prior treatment: Many trials require specific prior lines of therapy ("must have received at least one prior platinum-based regimen")
Performance status: ECOG 0–1 is typically required; ECOG 2 is sometimes allowed
Autoimmune disease: Active autoimmune conditions often exclude patients from checkpoint inhibitor trials due to risk of immune-related adverse events

Understanding Immune-Related Adverse Events (irAEs)

The same immune activation that fights cancer can affect normal tissues. Common irAEs include colitis (diarrhea), pneumonitis (lung inflammation), hepatitis, skin rash, and endocrinopathies (thyroid dysfunction, adrenal insufficiency). Most are manageable with corticosteroids and temporary drug hold; severe irAEs require permanent discontinuation.

Combination checkpoint inhibitor therapy (e.g., ipilimumab + nivolumab) has higher response rates but also higher irAE rates than monotherapy. Trial teams monitor closely with regular blood tests and patient-reported symptom diaries.

Finding a Cancer Immunotherapy Trial

Cancer patients should discuss trial eligibility with their oncologist at a National Cancer Institute (NCI)-designated cancer center, where most major immunotherapy trials are conducted. The NCI's Cancer Information Service (1-800-4-CANCER) can help identify trials. ClinicalMetric aggregates all currently recruiting cancer trials from ClinicalTrials.gov and allows filtering by condition and recruiting status.